Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis

NCT05821010 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-08-27

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and fructo-oligosaccharides with and without conditioned vegan lyophilized fecal microbiota transplantation capsules to reduce NASH in patients with fibrotic NASH. The main questions to answer are:

1. Can NASH be treated by altering the gut microbiota using LFMT capsules?
2. Can NASH be treated using a syntrophic cocktail of synbiotics and will these strains strengthen the effect of FMT?
3. What are the underlying mechanism by which the aforementioned treatments attenuate NASH?

Participants will be treated with FMT-capsules or placebo, and all participants will receive a cocktail of 3 strains of probiotics and one type of prebiotic.

Conditions

  • Non Alcoholic Steatohepatitis
  • Non-Alcoholic Fatty Liver Disease
  • Fecal Microbiota Transplantation
  • FMT
  • Prebiotics
  • Probiotics
  • Microbiome
  • Intestinal Microbiome
  • Gut Microbiome

Interventions

COMBINATION_PRODUCT

Lyophilized fecal microbiota transplantation capsules

Oral administration (capsule)

COMBINATION_PRODUCT

Placebo capsules

Oral administration (capsule)

DIETARY_SUPPLEMENT

A. soehngenii

Oral administration (capsule)

DIETARY_SUPPLEMENT

Pasteurized A. muciniphila

Oral administration (capsule)

DIETARY_SUPPLEMENT

B. animalis subsp. lactis

Oral administration (capsule)

DIETARY_SUPPLEMENT

Fructo-oligosaccharides

Oral administration (dissolved in water)

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • A.G. Holleboom, MD, PhD · Amsterdam UMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-17
Primary Completion
2026-02-20
Completion
2026-08-20

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05821010 on ClinicalTrials.gov